


In Vitro Systems Toxicology Assessment of Exposure to Aerosol from a Carbon Heated Tobacco Product as Compared with Exposure to Cigarette Smoke: The Impact on Nasal and Small Airway Epithelial Cultures

Anita R. Iskandar, Yannick Martinez, Carole Mathis, Patrice Leroy, Florian Martin, Alan Sewer, Laura Ortega Torres, Shoaib Majeed, Keyur Trivedi, Stefan Frentzel, Emmanuel Guedj, Celine Merg, Ashraf Elamin, Nikolai V. Ivanov, Manuel C. Peitsch, Julia Hoeng
Philip Morris International R&D, Philip Morris Products S.A., Neuchâtel, Switzerland (part of Philip Morris International group of companies)

Introduction

Toxicological assessment of tobacco products should provide relevant indication of the health risk for humans. Advances in tissue engineering have allowed the development of in vitro organotypic cultures with an air-liquid interface, thus permitting a direct exposure to inhaled chemicals. Using human organotypic nasal and small airway epithelial cultures, this study assessed the impact of an aerosol from a carbon heated tobacco product (CHTP) 1.2—a candidate modified-risk tobacco product (MRTP)*—compared with cigarette smoke (CS) at similar nicotine levels. Various endpoints including cytotoxicity, histology, ciliary beating function, cytochrome P450 1A1/1B1 activity, and secreted pro-inflammatory mediators, were complemented by a systems biology analysis of the transcriptomes to assess the exposure impact at different post-exposure time points. The overall data demonstrate a substantially reduced biological impact of CHTP1.2 aerosol exposure compared with CS in both nasal and small airway cultures.

Materials & Methods



Exposure Characterization:			Post-Exposure Measurements			
Nicotine concentrations in smoke/aerosol						
Biological Endpoint:	Before	After	4 h	24 h	48 h	72 h
Culture histology					x	x
Cytotoxicity			x	x	x	x
Secreted mediators				x	x	x
Transcriptomics			x	x	x	x
Ciliary beating analysis	x	x		x	x	x

Concentration of Nic (mg/L)	
3R4F	CHTP1.2
0.00 (Air)	0.00 (Air)
0.16	0.15
0.26	0.30
-	0.40

The impact of 28 min exposure to CS (from 3R4F reference cigarette, University of Kentucky) and to aerosol (from CHTP1.2, Philip Morris International R&D) were assessed using human organotypic nasal cultures (reconstituted from the nasal epithelial cells of a 41 year-old female, nonsmoker donor) and small airway cultures (reconstituted from the small airway epithelial cells of a 55 year-old female, nonsmoker donor). A paired design was implemented so that in parallel to the exposure to CS or to CHTP1.2 aerosol, the cultures were also exposed in the same exposure module and during the same exposure run to air. For each of the culture models, a series of experimental repetitions was conducted to increase the assessment robustness (N = 3 exposure runs/repetition).

Characterization of the 3R4F smoke and CHTP1.2 aerosol in the exposure system (Vitro-cell 24/48®) includes the measurements of nicotine in the diluted 3R4F smoke and THS2.2 aerosol throughout the studies. The diluted smoke/aerosol was trapped in Extralut 3NT® column and subjected to gas chromatography-flame ionization detection to determine the nicotine concentrations at the specific dilutions within each experimental week.

Cytotoxicity was assessed by measuring the adenylate kinase activity in the basolateral medium of the cultures using ToxiLight™ bioassay kit (Lonza, Rockland, MA, USA), according to the manufacturer's instructions.

For the histological analysis, the cross-sections of the organotypic epithelium cultures were analysed after hematoxylin and eosin and alcian blue staining.

Concentrations of pro-inflammatory mediators were measured from the basolateral medium of the exposed cultures using Luminex® xMAP® technology and commercially available assay panels (EMD Millipore Corp) according to the manufacturer's instructions. The culture media were collected at different post-exposure time points.


mRNA microarrays were done using 100 ng of total RNA (per sample) that were reverse-transcribed and amplified to cRNA using the Affymetrix® HT 3' IVT PLUS kit. Causal network enrichment analysis was done using the Network Perturbation Amplitude (NPA) methodology (Hoeng et al., 2014; Martin et al., 2012; Martin et al., 2014) was used to contextualize high dimensional transcriptomics data by combining gene expression (log₂ fold-changes into fewer differential node values (one value for each node of a causal biological network model). The collection of causal biological networks used in the study(s) was the human network suite CBN v1.3 (Boué et al., 2015).

References

***Family Smoking Prevention and Tobacco Control Act, 2009.** The term modified risk tobacco product (MRTP) is defined by the US Family Smoking Prevention and Tobacco Control Act (FSPTCA, 2009), and is to be understood as a general term which covers any product option, including e-cigarettes, electronic nicotine delivery systems (ENDS), and potential reduced exposure products (PREPs). The term "modified risk tobacco product" means any tobacco product that is sold or distributed for use to reduce harm or risk of tobacco-related diseases associated with commercially marketed tobacco products. **BOUE, S., et al. 2015.** Causal biological network database: a comprehensive platform of causal biological network models focused on the pulmonary and vascular systems. Database, 2015, bav030. **HOENG, J., et al. 2014.** Case study: the role of mechanistic network models in systems toxicology. Drug discovery today, 19, 183-192. **MARTIN, F., et al. 2014.** Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models. BMC Bioinformatics, 15, 238. **MARTIN, F., et al. 2012.** Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks. BMC systems biology, 6, 54.


Results

Culture Histology 72 h After Exposure



Hematoxylin-Eosin/Alcian Blue staining was performed in cultures 72 h post-exposure to 3R4F smoke or CHTP1.2 aerosol. At comparable nicotine concentration (0.27 - 0.30 mg/L), damage to the epithelial layer was observed in cultures exposed to 3R4F smoke but not in those exposed to CHTP1.2 aerosol.

Cytotoxicity 72 h Post-Exposure



Cytotoxicity levels were determined based on the levels of adenylate kinase released into the basolateral media following exposure. Upon cellular damage, adenylate kinase is released from the intracellular to the extracellular compartment. The level of cytotoxicity was reported relative to the Triton X-treated cultures (considered as 100% cytotoxicity). Greater cytotoxicity levels were observed following exposure to the higher concentration of 3R4F smoke. Less cytotoxicity levels were observed following exposure to all concentrations of CHTP1.2 aerosol. ★ p-value < 0.05 vs. its corresponding air control. #p-values 0.05 between CHTP1.2 and 3R4F at comparable concentrations.



Secretion of Pro-inflammatory Mediators Following Exposure

24 h Post-Exposure		48 h Post-Exposure		72 h Post-Exposure	
Nasal	4672 6036 3682 4670 4642 5049	9075 13614 9710 7595 16543 11456	9886 16286 9892 10732 8526 11229	CXCL1	
	1546 4604 783 995 1149 1685	1607 7749 1484 1886 2648 3577	2373 6357 1988 2445 2049 2898	CXCL8	
	22 34 20 23 23 25	66 104 51 65 62 83	82 100 59 70 48 71	CCL20	
	1526 2921 976 1242 1134 1018	5369 4974 2742 4108 3380 3886	6013 5704 2568 3922 2754 3794	MMP-1	
	5549 8211 3412 7411 8795 7240	17502 30196 5962 20334 19501 21351	26420 33184 13779 16886 16461 16918	MMP-9	
	5479 4297 3685 2763 2929 4466	9832 14096 22455 17650 19003 19235	17511 34076 19291 15565 11313 18974	TIMP1	
	91 290 98 144 175 259	183 549 264 206 250 341	332 888 444 355 424 705	VEGFA	
	Air (0.15) Air (0.14) (0.26) (0.54)	Air (0.15) Air (0.14) (0.26) (0.54)	Air (0.15) Air (0.14) (0.26) (0.54)		
3R4F		CHTP1.2		3R4F	
Small Airway	8237 7488 7241 7611 10980 7327	22731 21719 24801 24450 20722 19388	46986 120539 27699 30953 25398 24390	CXCL1	
	2655 8852 2436 2584 6435 5094	6926 17823 7386 7819 8065 8629	20287 63860 8939 9404 10659 9778	CXCL8	
	23 73 33 21 59 42	84 159 84 94 60 86	93 224 98 89 77 58	CCL20	
	876 11211 691 659 2655 2822	2218 19652 1997 2421 3171 5223	18515 32736 4055 3783 5773 5856	MMP-1	
	3639 11202 2968 1982 12027 6495	12751 31834 9571 10925 12791 20359	52706 72830 17933 13620 25574 23352	MMP-9	
	2737 6720 2625 2955 3487 3923	4804 23934 4109 4820 6104 7117	5622 54829 6161 5861 7124 9062	TIMP1	
	92 239 90 95 117 155	232 828 213 241 343 294	426 686 349 324 347 443	VEGFA	
	Air (0.16) Air (0.15) (0.30) (0.40)	Air (0.16) Air (0.15) (0.30) (0.40)	Air (0.16) Air (0.15) (0.30) (0.40)		
3R4F		CHTP1.2		3R4F	


Lowest to the highest concentration (mean, pg/mL) per mediator (row)

Various mediator concentrations secreted from the cells were measured to assess the inflammatory response of the cultures following 3R4F smoke and CHTP1.2 aerosol exposure. Numbers indicate the mean concentrations of pro-inflammatory mediator secreted into the basolateral media following exposure to 3R4F smoke and CHTP1.2 aerosol (N = 9 per group for nasal; N = 6 for small airway). Only the cultures exposed to the smoke or aerosol at sub-toxic levels were included, i.e., the samples exposed to the higher dose of 3R4F smoke were excluded. Relative to the air-exposed samples, the concentrations of the secreted mediators were markedly increased following 3R4F smoke exposure. In general, smaller alterations in the mediator concentrations were observed following CHTP1.2 aerosol at all doses tested, even at a dose where the nicotine concentrations were more than twice of the nicotine concentrations in 3R4F smoke.

Perturbation of Biological Pathways and Processes Following Exposure: Network-based Analysis of Transcriptome Profiles



A network-based systems biology approach was conducted using transcriptomics data from cultures exposed to the smoke or aerosol at sub-toxic levels, i.e., the samples exposed to the higher dose of 3R4F smoke were excluded. This approach uses biological network models that contain a series of cause-and-effect relationships (Boué et al., 2015). The network models can be grouped into network families, representing more general biological processes (e.g., Cell Proliferation, Cell Fate, Cell Stress, or Inflammatory Process Networks network). CHTP1.2 aerosol-induced network perturbations were lower than those following 3R4F smoke (N = 9 per group in nasal; N = 6 per group in small airway studies). NPA, network perturbation amplitude.



The heatmap lists only the MIRNAs that were differentially expressed following exposure in at least one contrast in both culture types. The results show that 3R4F smoke exposure was linked to more substantial MIRNA changes as compared with CHTP1.2 aerosol at all concentrations tested (N = 9 per group in nasal; N = 6 per group in small airway studies).

Conclusions

Collectively, the results show that the impact of CHTP1.2 aerosol on nasal epithelium was considerably lower than 3R4F smoke at similar nicotine concentrations, in regard to:

- Cytotoxicity levels (based on the levels of adenylate kinase released into the basolateral media) and culture morphology at 72 h post-exposure
- Inflammatory responses (based on the secreted pro-inflammatory mediator levels) following exposure
- Perturbation of biological processes (modeled in the causal network models) derived from the global gene expression and MIRNA changes following exposure.

Using this systems toxicology approach, biological processes and/or signaling pathways could be identified from the global gene expression changes that were not captured by the classical functional measures (culture morphology, cytotoxicity, and secretion of pro-inflammatory mediators). As compared with the biological impact of 3R4F smoke, the aerosol from the candidate modified-risk tobacco product CHTP1.2 elicited much lower impact in all measured endpoints in the human nasal and small airway cultures, even when the nicotine concentrations in the CHTP1.2 aerosols were 2-3 times higher than that in 3R4F smoke.

Competing Financial Interest

The research described in this poster was sponsored by Philip Morris Products SA